Use of a tsrna in the diagnosis, prevention and treatment of neuromyelitis optica spectrum disorders
By detecting the expression level of tsRNA tRF-19-40 in plasma, a diagnostic and disease monitoring model for NMOSD was constructed, which solved the problem of early diagnosis of NMOSD in existing technologies, achieved efficient disease assessment and treatment, and improved diagnostic accuracy and treatment efficacy.
Patent Information
- Application Number
- CN202611253154.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-18
- Publication Date
- 2026-11-17
AI Technical Summary
Existing diagnostic methods for NMOSD are insufficient for accurately assessing disease activity and predicting recurrence risk, resulting in low early diagnosis rates, delayed intervention, and a lack of stable and efficient molecular markers.
Using plasma-derived tsRNA tRF-19-40 as a biomarker, its expression level was detected by specific probes or PCR primers. A Firth regression analysis model was constructed for diagnosis and disease monitoring, and corresponding treatment plans were provided. Inhibitors were used to reduce excessive inflammatory response in astrocytes.
tRF-19-40 exhibits high specificity and sensitivity in diagnosis, enabling accurate assessment of disease severity, significantly improving early diagnosis rates, and providing effective treatment by inhibiting its expression or activity to reduce inflammatory responses.
Smart Images

Figure CN123108138A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the fields of biology and medicine, specifically to the application of tsRNA (tRNA-derived small RNA) in the preparation of products for the diagnosis, disease monitoring, prevention and treatment of neuromyelitis optica spectrum disorders. Background Technology
[0002] Neuromyelitis Optica Spectrum Disorders (NMOSD) is a rare autoimmune inflammatory demyelinating disease of the central nervous system, predominantly affecting women, with acute optic neuritis and myelitis as the main clinical manifestations (Non-Patent Literature 1). NMOSD is characterized by high relapse and high disability rates; approximately 90% of patients experience relapse within 3 years of onset, and 50% suffer from irreversible visual impairment, motor dysfunction, and other sequelae within 5–10 years of disease progression, severely impacting their quality of life (Non-Patent Literature 2, 3). Therefore, early identification, accurate diagnosis, and long-term relapse prevention are crucial for improving the prognosis of NMOSD patients and reducing the risk of disability.
[0003] The etiology of NMOSD is not yet fully understood, and its clinical manifestations are highly heterogeneous with atypical early symptoms. Currently, clinical diagnosis mainly relies on a comprehensive assessment of medical history, core clinical symptoms, imaging features, and biomarkers, which makes it difficult to achieve early warning, accurate disease assessment, and prognosis prediction. There is an urgent need to discover stable and efficient new molecular biomarkers.
[0004] tsRNA-derived small RNAs (tsRNAs) are a class of novel non-coding RNAs formed by the cleavage and processing of mature tRNA or tRNA precursors. They are typically 14-50 nucleotides in length and mainly comprise two subtypes: tRNA-derived fragments (tRFs) and tRNA half-molecules (tiRNAs) (Non-Patent Literature 4). tsRNAs exhibit high stability in bodily fluids such as plasma and cerebrospinal fluid, and specific abnormal expression profiles of tsRNAs, distinct from those in healthy individuals, have been detected in various central nervous system diseases (Non-Patent Literature 5, 6). Furthermore, tsRNAs can regulate glial cell inflammatory responses and participate in the development and progression of central nervous system damage (Non-Patent Literature 7, 8). Therefore, they possess excellent potential as biomarkers for the clinical diagnosis and monitoring of central nervous system diseases.
[0005] Currently, no studies have systematically elucidated the expression characteristics and biological functions of tsRNA in NMOSD, and there are still gaps in related research. Therefore, the development of novel non-invasive biomarkers for diagnosing or assessing NMOSD from test samples remains an urgent need.
[0006] Non-patent literature Non-patent literature 1: Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6(1):85.Published 2020 Oct 22. Non-patent literature 2: Tian DC, Li Z, Yuan M, et al. Incidence of neuromyelitisoptica spectrum disorder (NMOSD) in China: A national population-based study[published correction appears in Lancet Reg Health West Pac. 2021 Mar 02;8:100118]. Lancet Reg Health West Pac. 2020;2:100021. Non-patent literature 3: Neuroimmunology Group of Neurology Branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of neuromyelitis optica spectrum disorders in China (2025 edition) [J]. Chinese Journal of Neurology, 2025, 58(7):687-703. Non-patent literature 4: Zhang L, Liu J, Hou Y. Classification, function, and advances in tsRNA in non-neoplastic diseases[J]. Cell Death Dis. 2023;14(11):748. Non-patent document 5: Wu W, Lee I, Spratt H, Fang X, Bao X. tRNA-DerivedFragments in Alzheimer's Disease: Implications for New Disease Biomarkers andNeuropathological Mechanisms. J Alzheimers Dis. 2021;79(2):793-806. Non-patent literature 6: Magee R, Londin E, Rigoutsos I. TRNA-derived fragments assex-dependent circulating candidate biomarkers for Parkinson's disease. Parkinsonism Relat Disord. 2019;65:203-209. Non-patent literature 7: Dong X, Li Q, Li R, et al. Inhibition of tRF- 02514 inExtracellular Vesicles Preserves Microglia Pyroptosis and Protects AgainstParkinson's Disease. Mol Neurobiol. 2025;62(9):11047-11063. Non-patent literature 8: Zhang Y, Ma Y, Ji YK, et al. Co-targeting of glialactivation and inflammation by tsRNA-Gln-i-0095 for treating retinal ischemicpathologies. Cell Commun Signal. 2025;23(1):18. Published 2025 Jan 10. Summary of the Invention Existing diagnostic methods for NMOSD struggle to accurately assess disease activity and predict relapse risk, resulting in low early diagnosis rates and delayed intervention. In light of these issues, this invention conducted in-depth research and discovered that a tsRNA derived from plasma (tRF-19-40, whose nucleotide sequence is shown in SEQ ID NO: 1) can serve as a highly specific and sensitive biomarker for diagnosing and monitoring NMOSD. This invention establishes a method for diagnosing and monitoring NMOSD based on tRF-19-40 and provides a treatment regimen targeting this biomarker.
[0007] To achieve the above objectives, the present invention employs the following technical solution: In a first aspect, the present invention provides the use of a reagent for detecting the expression level of the neuromyelitis optica spectrum disease (NMOSD) biomarker tRF-19-40 in the preparation of diagnostic and / or disease monitoring products for NMOSD, wherein the nucleotide sequence of said tRF-19-40 is as shown in SEQ ID NO: 1.
[0008] In some embodiments, the reagent for detecting tRF-19-40 expression levels includes a specific probe or PCR primers; in some preferred embodiments, the PCR primers are sequences as shown in SEQ ID NO: 2 and SEQ ID NO: 3, respectively.
[0009] In some implementations, the analytical method for detecting tRF-19-40 expression levels uses qRT-PCR, with U6 small non-coding RNA as an internal reference gene, and the fold change of the disease group relative to the control group (set as 1) is calculated using the 2^-ΔΔCt value.
[0010] In some preferred embodiments, a diagnostic cutoff value of ≥2.2862 for the relative expression level of tRF-19-40 is considered NMOSD positive, and a diagnostic cutoff value <2.2862 is considered NMOSD negative; the cutoff value is determined based on the Youden exponent maximization principle.
[0011] In some implementations, the diagnosis and / or monitoring of NMOSD is based on a risk prediction model constructed using Firth regression analysis, wherein the linear prediction equation output by the Firth regression is: P is the predicted probability of an individual having NMOSD, and X is the relative expression level of tRF-19-40; In some preferred embodiments, a high risk of NMOSD is determined when P ≥ 0.5301.
[0012] In some embodiments, the test sample for the diagnostic and / or disease monitoring product for NMOSD is plasma; in some preferred embodiments, the plasma is peripheral plasma.
[0013] In a second aspect, the present invention provides a diagnostic kit for detecting NMOSD, wherein the kit includes primers for specifically amplifying the NMOSD biomarker tRF-19-40; wherein the nucleotide sequence of tRF-19-40 is shown in SEQ ID NO: 1.
[0014] In some embodiments, the primers are sequences as shown in SEQ ID NO: 2 and SEQ ID NO: 3, respectively.
[0015] In a third aspect, the present invention provides the use of an inhibitor of tRF-19-40 in the preparation of a medicament for the prevention and / or treatment of NMOSD; wherein the inhibitor reduces the excessive inflammatory response of astrocytes by inhibiting the expression or activity of tRF-19-40, thereby achieving the purpose of preventing and / or treating NMOSD, wherein the nucleotide sequence of tRF-19-40 is as shown in SEQ ID NO: 1.
[0016] In some embodiments, the inhibitor is selected from one or more of antisense oligonucleotides, siRNA, small molecule inhibitors, ribozymes, nucleic acid aptamers, and antibodies.
[0017] In a fourth aspect, the present invention provides a computer-readable storage medium storing a computer program that, when executed by a processor, is used to instruct the diagnosis of NMOSD, wherein, when the program is run on a computer, it includes the following method: detecting the presence or expression level of the NMOSD biomarker tRF-19-40, and generating output data representing the risk level of a subject having NMOSD based on the detection result; wherein the nucleotide sequence of tRF-19-40 is as shown in SEQ ID NO: 1; In some preferred embodiments, the method performs the following steps: (a) Receive the relative expression level data X of tRF-19-40 in the sample to be tested; (b) According to the Firth regression equation Calculate the predicted probability P of an individual having NMOSD; when P ≥ 0.5301, the individual is considered to be at high risk for NMOSD. In some preferred embodiments, the relative expression level data of tRF-19-40 is obtained by qRT-PCR, with U6 small non-coding RNA as the internal reference gene, and the value is calculated using 2^-ΔΔCt. If X≥2.2862, "NMOSD high risk" is output; otherwise, "NMOSD low risk" is output.
[0018] Compared with the prior art, the present invention has the following beneficial effects: The NMOSD biomarker tRF-19-40 provided by this invention has the following favorable characteristics: ① High diagnostic value: In a cohort of 18 NMOSD patients, the expression level of tRF-19-40 was significantly higher than that of the healthy control group. The AUC calculated based on the Firth regression model was 1.000, and the sensitivity and specificity were both 1.000, indicating that tRF-19-40 has high diagnostic efficacy for NMOSD. ② Correlation with disease severity: Pearson correlation analysis showed that the expression level of tRF-19-40 was significantly positively correlated with the patient's baseline EDSS score (r=0.684), which can be used to assess the severity of the disease; ③ Clear biological function: In vitro cell experiments confirmed that tRF-19-40 overexpression can induce astrocyte damage, leading to a significant decrease in cell activity, and significantly upregulate the expression levels of A1 pro-inflammatory astrocyte marker C3 and core inflammatory factors such as IL-1α, IL-1β, and IL-6, revealing that tRF-19-40 is a key functional molecule mediating NMOSD-related astrocyte lesions; ④ Clear clinical application prospects: Decision curve analysis (DCA) confirms that this predictive model can achieve higher net clinical benefits and has good prospects for clinical translation and application. Attached Figure Description
[0019] Figure 1 This is a flowchart illustrating the strategy for the two-stage research and analysis of candidate tsRNA discovery and validation in this invention. Figure 2 The results are the high-throughput tsRNA sequencing data of this invention; where A represents the tsRNA length distribution data of NMOSD patients and healthy controls; B is the differential tsRNA volcano plot; red represents upregulated tsRNA with a fold change FC ≥ 2, and green represents fold change FC ≤ 2. Downregulation of tsRNA by 2; Figure 3 To detect the relative expression level of tRF-19-40 of the present invention in the plasma of NMOSD patients in the discovery set using qRT-PCR; Figure 4 This is a schematic diagram showing the generation source and secondary structure of tRF-19-40 in this invention; Figure 5 The relative expression level of tRF-19-40 of the present invention in the plasma of NMOSD patients in the validation set was detected by qRT-PCR. Figure 6 Correlation analysis of the expression level of tRF-19-40 in this invention with the baseline Extended Disability Status Scale (EDSS) score of patients; Figure 7 The ROC curve analysis results of tRF-19-40 of this invention; Figure 8 The results of the decision curve analysis of the tRF-19-40 of this invention; Figure 9 The relative expression level of tRF-19-40 of the present invention in the NMOSD cell model group was detected by qRT-PCR. Figure 10The results show the morphological and survival phenotypes of astrocytes. A represents the morphological changes in astrocytes after tRF-19-40 overexpression observed under bright-field microscopy, and the survival status of astrocytes characterized by live / dead cell fluorescence staining. B represents the quantitative statistics of the number of astrocytes in bright-field images. C represents the quantitative statistics of cell survival rate in the live / dead cell staining results. D represents the cell viability of astrocytes after tRF-19-40 overexpression detected by the CCK-8 assay. Figure 11 The results show the transcriptional and protein secretion levels of inflammatory factors. Among them, A to F represent the mRNA expression levels of inflammation-related genes IL1A, IL1B, IL1R1, IL6 and polarization-related genes C3 and S100A10 in cells, detected by qRT-PCR, respectively; G to I represent the protein secretion levels of inflammatory factors IL-1α, IL-1β and IL-6 in cell supernatant, detected by ELISA, respectively. Detailed Implementation
[0020] To enable those skilled in the art to better understand the present invention, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings of the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort should fall within the scope of protection of the present invention.
[0021] It should be noted that the terms "comprising" and "having" and any variations thereof in this invention are intended to cover non-exclusive inclusion. For example, a process, method, system, product, or device that includes a series of steps or units is not necessarily limited to those steps or units that are explicitly listed, but may include other steps or units that are not explicitly listed or that are inherent to such process, method, product, or device.
[0022] The present invention will now be described in further detail with reference to the accompanying drawings: Example 1: Obtaining the expression profile of plasma tsRNAs in NMOSD patients and discovering candidate tsRNAs The study included 18 female patients with acute AQP4-IgG positive NMOSD who visited the Department of Neurology and Ophthalmology at Xi'an First Hospital between May and December 2025. Eighteen age-, sex-, and baseline matched healthy volunteers (HCs) were also recruited. This study employed a classic two-stage experimental design: a discovery set and a validation set. The discovery set included plasma samples from 6 NMOSD patients (NMOSD1–6) and 6 healthy controls (HC1–6) for high-throughput tsRNA sequencing to obtain the plasma tsRNA expression profiles of NMOSD patients. The validation set included plasma samples from 12 patients (NMOSD7–18) and 12 healthy controls (HC7–18) for qRT-PCR validation of candidate differentially expressed tsRNAs. Furthermore, clinical evaluation and functional analysis were used to further clarify the application value of candidate tsRNAs. The strategy and workflow for the two-stage study of candidate tsRNA discovery and validation are as follows: Figure 1 As shown.
[0023] tsRNA high-throughput sequencing was performed by DataSpectrum (Shanghai) Biotechnology Co., Ltd., and the sequencing data results are shown in Table 1. Figure 2 As shown; where, Figure 2 A represents the tsRNA fragment length data; Figure 2 B represents differential tsRNA expression data.
[0024] Table 1 Sequencing data of NMOSD patients and HC samples
[0025] Table 1 shows that the Q30 values of sequencing data from all NMOSD patients and HC samples were >90%, indicating that the sequencing data are of reliable quality and high credibility, and can be used for subsequent analysis. Figure 2 As shown in Figure A, the tsRNA fragment lengths discovered in this invention are mainly concentrated in two regions: 20–23 nt and 31–32 nt. Figure 2 As shown in B, this invention used |FC|≥2 and P<0.05 as differential screening thresholds, and screened out a total of 1358 differentially expressed tsRNAs, of which 565 were upregulated and 793 were downregulated in the patient group. Based on the balanced distribution of CPM expression levels among the groups, this invention obtained one candidate tsRNA, named tRF-19-40, with a molecular length of 22 nt. Its nucleotide sequence (5'→3') is shown below: TATGATTTCTCGCTTCGGGTGCG, SEQ ID NO:1.
[0026] The expression level of tRF-19-40 in the discovery collection plasma was verified by qRT-PCR. The experimental steps are as follows: (1) Plasma RNA extraction: ① Remove the plasma sample from the -70℃ freezer, thaw it, and centrifuge it at 12,000×g for 10 min at 4℃. Take 250 μl of plasma liquid, transfer it to a 1.5 ml centrifuge tube, and add 750 μl of TRIzol LS Reagent (Thermo Fisher Scientific, USA).
[0027] ② Add 0.2 ml of chloroform, tighten the cap, shake the tube vigorously by hand for 15 seconds, place it on ice for 5 minutes, and centrifuge at 12,000×g for 15 minutes at 4℃.
[0028] ③ Transfer the upper aqueous phase to a new centrifuge tube, add 500 μl of isopropanol, mix well to precipitate the RNA, place on ice for 10 min, and centrifuge at 12,000×g for 10 min at 4℃.
[0029] ④ Discard the supernatant, add 1 ml of 75% ethanol to wash the RNA precipitate, vortex, and centrifuge at 7,500×g for 5 min at 4℃.
[0030] ⑤ Discard the supernatant, air-dry the RNA precipitate for 5-10 min, add 40 μl of RNase-free water to dissolve the RNA, and store the obtained RNA solution at -70℃.
[0031] (2) cDNA synthesis First, RNA was pretreated using the rtStar™ tRF&tiRNA Pretreatment Kit (Cat# AS-FS-005, Arraystar, USA). Then, cDNA was synthesized by reverse transcription using the rtStar™ First-Strand cDNA Synthesis Kit (Cat# AS-FS-003, Arraystar, USA). All experiments were performed according to the kit instructions.
[0032] (3) qPCR Finally, qPCR was performed using a 2×PCR master mix (Cat# AS-MR-006-5, Arraystar, USA). U6 small non-coding RNA was used as an internal reference gene. The relative expression levels of candidate tsRNAs were calculated using the 2^-ΔΔCt method. Three replicates were used for each sample group to reduce experimental error. The experimental composition was: 5 μl 2×Master Mix, 0.5 μl tRF-19-40 primer F, 0.5 μl tRF-19-40 primer R, 2 μl cDNA, and ddH2O to a final volume of 10 μl. The PCR reaction program was as follows: 95℃, 10 min; 40 PCR cycles (95℃, 10 s; 60℃, 60 s (collect fluorescence). To establish the melting curve of the PCR product, after the amplification reaction, the cycle was (95℃, 10 s; 60℃, 60 s; 95℃, 15 s). The temperature was then slowly increased from 60℃ to 95℃ (automatically by the instrument - Ramp Rate was 0.075℃ / s).
[0033] The primer sequence for tRF-19-40 is shown below: F (upstream, 5'→3'): CCGACGATCTATGATTCTCGC, SEQ ID NO: 2 R (downstream, 5'→3'): GCTCTTCCGATCTCGCACC, SEQ ID NO: 3 The verification results are as follows Figure 3 The results showed that the expression level of tRF-19-40 in the plasma of NMOSD patients was significantly higher than that in the HC group (set as 1).
[0034] Example 2: Validation of the application of tRF-19-40 in NMOSD diagnosis 2.1 Analysis of the tRF-19-40 subtype Existing research classifies tRFs into four classic isotypes—5'-tRF, 3'-tRF, i-tRF, and 2-tRF—based on sequence fragment location and tRNA precursor cleavage characteristics. This invention discovers that tRF-19-40 originates from tRNA-Pro-CGG-1-1. Combining sequence characteristics with genomic mapping analysis, it was found that the cleavage sites of tRF-19-40 do not match the characteristic cleavage regions of the four classic tRF isotypes. Therefore, it is classified as the Other-tRF isotype. The results are as follows: Figure 4 The diagram shows the origin of tRF-19-40 and the secondary structure of tRNA.
[0035] 2.2 Validation of tRF-19-40 expression levels This invention further included an independent validation cohort consisting of 12 NMOSD patients (NMOSD7-18) and 12 healthy controls (HC7-18) for qRT-PCR validation. The validation experiment followed the method described in Example 1, and the results are as follows. Figure 5 As shown, the expression level of tRF-19-40 in the plasma of NMOSD patients was significantly higher than that in the HC group (set as 1), and the difference between the groups was statistically significant.
[0036] 2.3 Research on the Correlation between tRF-19-40 Expression Levels and Clinical Indicators This invention clarifies the clinical application value of tRF-19-40 in NMOSD by analyzing the correlation between the expression level of tRF-19-40 in the plasma of NMOSD patients (NMOSD1~18) and various clinical indicators.
[0037] 2.3.1 Pearson Correlation Analysis The results of the Pearson correlation analysis are as follows: Figure 6 As shown, the expression level of tRF-19-40 (NMOSD7~18) was significantly positively correlated with the baseline Extended Disability Status Scale (EDSS) score of patients, with a correlation coefficient of 0.684.
[0038] 2.3.2 Constructing a disease risk prediction model for NMOSD A disease risk prediction model for NMOSD was constructed using Firth regression analysis, and the ROC curve is shown below. Figure 7 As shown, the modeling steps are as follows: (1) Model building steps ① Data preparation: Plasma samples were collected from NMOSD patients (NMOSD1~18) and healthy controls (HC1~18). The expression level of tRF-19-40 relative to U6 was detected by qRT-PCR, and the group labels (disease = 1, healthy = 0) were recorded.
[0039] ② Univariate Firth Regression Fitting: The model is fitted using Firth penalized likelihood logistic regression (logistf R package). Firth regression can effectively handle the unbounded problem of conventional logistic regression coefficients caused by complete data separation (AUC=1), ensuring the stability of parameter estimation.
[0040] ③ Determination of the optimal cutoff value: Based on the original indicators, an ROC curve is plotted, and the optimal diagnostic cutoff value is determined by maximizing the Youden's index.
[0041] ④ Internal validation: Bootstrap resampling (500 times) was used for internal validation. The AUC, sensitivity, specificity and their 95% confidence interval after optimistic correction were calculated to evaluate the model’s generalization ability.
[0042] (2) Forecasting indicators This model is a univariate predictive model, using tRF-19-40 as the sole predictive biomarker without incorporating other variables. Since the current analysis does not include multi-indicator joint modeling, risk prediction relies entirely on the expression level of tRF-19-40.
[0043] (3) The formula for calculating disease risk and the meaning of the parameters The linear prediction equation for the Firth regression output is:
[0044] The formula for calculating the probability of disease P:
[0045] Parameter meaning: P: The predicted probability (0~1) of an individual having NMOSD.
[0046] X: Relative expression level of tRF-19-40.
[0047] 7.2463: Intercept, the log-risk baseline when the biomarker expression level is 0.
[0048] 3.2530: Regression coefficient, indicating that for every unit increase in this indicator, the logarithmic hazard increases by 3.2530; its index The odds ratio (OR) indicates that for every 1 unit increase in this indicator, the risk of developing the disease increases by approximately 25.87 times.
[0049] (4) Rules and standards for determining diagnostic results Based on maximizing the Yoden exponent, the optimal cutoff value is 2.2862. The determination rule is as follows: NMOSD (Non-Modular Disease) diagnosis: When X ≥ 2.2862, the prediction is positive.
[0050] Assuming health status (control): When X < 2.2862, the prediction is negative.
[0051] (5) Model performance and Bootstrap validation results Performance on the full dataset: AUC = 1.000, sensitivity = 1.000, specificity = 1.000 (complete separation exists, but Firth regression has corrected for coefficient bias).
[0052] Bootstrap internal validation (500 runs): Optimally corrected AUC = 1.000 (95% CI: 1.000–1.000); Corrected sensitivity based on a fixed cutoff value (2.2862) = 1.000 (95% CI: 1.000–1.000); Corrected specificity = 1.000 (95% CI: 1.000–1.000).
[0053] The performance metrics remain excellent after Bootstrap correction, indicating that the marker tRF-19-40 has extremely strong discriminative power in the current dataset and the threshold is stable.
[0054] Therefore, this model, based on the construction of a single tRF biomarker (tRF-19-40), provides a clear risk calculation formula and diagnostic threshold; current Bootstrap validation shows that this biomarker has high stability; Decision curve analysis (DCA) results ( Figure 8 This further confirms that the predictive model can achieve higher net clinical benefits and has good prospects for clinical translation and application.
[0055] In summary, the biomarker tRF-19-40 of this invention can be used as a tool for diagnosing NMOSD.
[0056] Example 3: Study on the biological role of tRF-19-40 in NMOSD 3.1 Expression of tRF-19-40 in the NMOSD cell model group This invention further investigates the biological role of tRF-19-40 in NMOSD. The specific experimental methods are as follows: Human astrocyte colony-stimulating cell line SVGP12 (purchased from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences, TCHU258) was passaged in a 37℃, 5% CO2 incubator. Cells in the 3rd–5th generation logarithmic growth phase were selected for subsequent experiments. The pathological microenvironment of NMOSD was simulated in vitro by incubating SVGP12 cells in DMEM high-glucose basal medium containing 40% NMOSD patient / HC inactivated plasma and 20% human mixed complement serum (PHCS, Innovative Research, USA) for 24 h. After treatment, cells were collected, and tRF-19-40 expression was detected by qRT-PCR. The results are as follows: Figure 9 The results showed that, consistent with the expression trend in clinical samples, tRF-19-40 exhibited a significantly higher expression trend in the NMOSD cell model group compared to the control group.
[0057] 3.2 Biological Functional Studies of tRF-19-40 Both the tRF-19-40 mimic and the negative control mimic NC were designed and synthesized by GenePharma. SVGP12 cells were seeded in 6-well plates, and when the adhesion rate reached 70%–80%, the transfection system was prepared according to the instructions using siRNA-mate plus transfection reagent (GenePharma, G04027) and transiently transfected at a final concentration of 20 μmol / L. Cells were collected 24 h after transfection for subsequent functional validation experiments.
[0058] 3.2.1 Observation of morphology and survival phenotype of astrocytes Cell viability was detected by CCK-8 assay, and live and dead cells were quantified by staining to observe the morphology and survival phenotype of astrocytes; results are as follows. Figure 10 As shown in AD.
[0059] Cell morphology and survival phenotype observations showed that, compared to the minic NC group, the number of astrocytes in the tRF-19-40 mimic overexpression group was significantly reduced, and typical pathological damage characteristics such as disordered cell body morphology, atrophy and breakage of processes, and large-scale cell shedding and fragmentation were observed. CCK-8 assays for cell viability and quantitative results from live and dead cell staining both confirmed that cell activity and survival rates were significantly decreased after tRF-19-40 overexpression.
[0060] 3.2.2 Detection of inflammatory factor transcription and protein secretion levels The mRNA transcription levels of genes related to the inflammation pathway were detected by qRT-PCR. The experimental steps are as follows: (1) Cell RNA extraction: ① Add 1 ml of TRIzol LS Reagent (Thermo Fisher Scientific, USA) to the processed cells, lyse them thoroughly, and then transfer them to a 1.5 ml centrifuge tube.
[0061] ② Add 0.2 ml of chloroform, tighten the cap, shake the tube vigorously by hand for 15 seconds, place it on ice for 5 minutes, and centrifuge at 12,000×g for 15 minutes at 4℃.
[0062] ③ Transfer the upper aqueous phase to a new centrifuge tube, add 500 μl of isopropanol, mix well to precipitate the RNA, place on ice for 10 min, and centrifuge at 12,000×g for 10 min at 4℃.
[0063] ④ Discard the supernatant, add 1 ml of 75% ethanol to wash the RNA precipitate, vortex, and centrifuge at 7,500×g for 5 min at 4℃.
[0064] ⑤ Discard the supernatant, air-dry the RNA precipitate for 5-10 min, add 40 μl of RNase-free water to dissolve the RNA, and store the obtained RNA solution at -70℃.
[0065] (2) qRT-PCR Reverse transcription and quantitative real-time PCR experiments were performed using the Evo M-MLV reverse transcription kit and SYBR Green Pro Taq HS premixed buffer (AG). ACTB was used as the internal reference gene, and the relative expression levels of each gene were calculated using the 2^-ΔΔCt method. The control group was set at 1.
[0066] The results are as follows Figure 11 In the study of AF, it was shown that overexpression of the tRF-19-40 mimic significantly upregulated the mRNA transcription level of C3, a marker of pro-inflammatory astrocytes in type A1; and simultaneously upregulated the mRNA transcription levels of core inflammatory genes such as IL1A, IL1B, IL1R1, and IL6. The protein secretion levels of IL-1α, IL-1β, and IL-6 inflammatory factors in cell supernatant were quantitatively detected by ELISA. The experimental steps are as follows: Collect cell culture supernatants from each group, centrifuge to remove cell debris, and then aliquot and store. Strictly follow the instructions of the ELISA kit (BOSTER) for IL-6, IL-1α, IL-1β, and IL36A, set up a standard gradient and a blank control, and measure the OD value at 450 nm using a microplate reader. Calculate the protein concentration of inflammatory factors in the supernatant of each group based on the standard curve to assess the level of cellular inflammatory activation.
[0067] The results are as follows Figure 11 The protein secretion levels of inflammatory factors GI, IL-1α, IL-1β, and IL-6 were simultaneously and significantly increased.
[0068] In summary, a series of experimental results on cell survival, morphology, and inflammation levels confirm that tRF-19-40 induces astrocyte damage, activates excessive inflammatory responses, and reproduces the core pathological features of NMOSD, making it a key functional molecule mediating NMOSD-related astrocyte lesions.
[0069] The above content is only for illustrating the technical concept of the present invention and should not be construed as limiting the scope of protection of the present invention. Any modifications made to the technical solution based on the technical concept proposed in this invention shall fall within the scope of protection of the claims of this invention.
Claims
1. The application of a reagent for detecting the expression level of the neuromyelitis optica spectrum disorder (NMOSD) biomarker tRF-19-40 in the preparation of diagnostic and / or disease monitoring products for NMOSD, characterized in that, The nucleotide sequence of tRF-19-40 is shown in SEQ ID NO:
1.
2. The application according to claim 1, characterized in that, The reagents used to detect tRF-19-40 expression levels include specific probes or PCR primers; Preferably, the PCR primers are sequences as shown in SEQ ID NO: 2 and SEQ ID NO: 3, respectively.
3. The application according to claim 1, characterized in that, The analytical method for detecting tRF-19-40 expression level was qRT-PCR, with U6 small non-coding RNA as the internal reference gene. The fold change of the disease group relative to the control group was calculated using the 2^-ΔΔCt value, where the control group was set as 1. Preferably, a diagnostic cutoff value of tRF-19-40 relative expression level ≥ 2.2862 is used to determine NMOSD positivity, and a diagnostic cutoff value < 2.2862 is used to determine NMOSD negativity; the cutoff value is determined based on the Youden exponent maximization principle.
4. The application according to claim 1, characterized in that, The diagnosis and / or monitoring of NMOSD are based on a risk prediction model constructed using Firth regression analysis, wherein the linear prediction equation output by the Firth regression is: P is the predicted probability of an individual having NMOSD, and X is the relative expression level of tRF-19-40; Preferably, when P ≥ 0.5301, it is determined to be a high risk of NMOSD.
5. The application according to claim 1, characterized in that, The test sample for the diagnostic and / or disease monitoring products used for NMOSD is plasma.
6. A diagnostic kit for detecting NMOSD, characterized in that, The kit includes primers for the specific amplification of the NMOSD biomarker tRF-19-40; wherein the nucleotide sequence of tRF-19-40 is shown in SEQ ID NO:
1.
7. The diagnostic kit according to claim 6, characterized in that, The primers are sequences as shown in SEQ ID NO: 2 and SEQ ID NO: 3, respectively.
8. The use of tRF-19-40 inhibitors in the preparation of medicaments for the prevention and / or treatment of NMOSD; characterized in that, The inhibitor reduces excessive inflammatory response in astrocytes by inhibiting the expression or activity of tRF-19-40, thereby preventing and / or treating NMOSD, wherein the nucleotide sequence of tRF-19-40 is shown in SEQ ID NO:
1.
9. The application according to claim 8, characterized in that, The inhibitor is selected from one or more of antisense oligonucleotides, siRNA, small molecule inhibitors, ribozymes, nucleic acid aptamers, and antibodies.
10. A computer-readable storage medium storing a computer program, which, when executed by a processor, is used to instruct the diagnosis of NMOSD, characterized in that, When the program is run on a computer, it includes the following method: detecting the presence or expression level of the NMOSD biomarker tRF-19-40; and generating output data representing the risk level of the subject having NMOSD based on the detection results; wherein the nucleotide sequence of tRF-19-40 is as shown in SEQ ID NO: 1; Preferably, the method performs the following steps: (a) Receive the relative expression level data X of tRF-19-40 in the sample to be tested; (b) According to the Firth regression equation Calculate the predicted probability P of an individual having NMOSD; when P ≥ 0.5301, the individual is considered to be at high risk for NMOSD. More preferably, the relative expression level data of tRF-19-40 is obtained by qRT-PCR, with U6 small non-coding RNA as the internal reference gene, and the value of 2^-ΔΔCt is used for calculation. If X≥2.2862, "NMOSD high risk" is output; otherwise, "NMOSD low risk" is output.
